IL233154D0 - Compounds - Google Patents

Compounds

Info

Publication number
IL233154D0
IL233154D0 IL233154A IL23315414A IL233154D0 IL 233154 D0 IL233154 D0 IL 233154D0 IL 233154 A IL233154 A IL 233154A IL 23315414 A IL23315414 A IL 23315414A IL 233154 D0 IL233154 D0 IL 233154D0
Authority
IL
Israel
Prior art keywords
compounds
Prior art date
Application number
IL233154A
Other languages
Hebrew (he)
Other versions
IL233154A (en
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB1122139.7A priority Critical patent/GB2497806A/en
Priority to GB201217290A priority patent/GB201217290D0/en
Priority to PCT/GB2012/053217 priority patent/WO2013093484A1/en
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL233154D0 publication Critical patent/IL233154D0/en
Publication of IL233154A publication Critical patent/IL233154A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
IL233154A 2011-12-21 2014-06-16 Compounds, pharmaceutical compositions comprising the same and uses thereof IL233154A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB1122139.7A GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
GB201217290A GB201217290D0 (en) 2012-09-27 2012-09-27 Compounds
PCT/GB2012/053217 WO2013093484A1 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors

Publications (2)

Publication Number Publication Date
IL233154D0 true IL233154D0 (en) 2014-08-03
IL233154A IL233154A (en) 2016-12-29

Family

ID=47553259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233154A IL233154A (en) 2011-12-21 2014-06-16 Compounds, pharmaceutical compositions comprising the same and uses thereof

Country Status (24)

Country Link
US (2) US9732085B2 (en)
EP (2) EP3290413B9 (en)
JP (2) JP6137193B2 (en)
KR (1) KR102011534B1 (en)
CN (1) CN104136431B (en)
AU (1) AU2012356374B2 (en)
BR (1) BR112014015669A8 (en)
CA (1) CA2859604C (en)
DK (1) DK2794597T3 (en)
ES (2) ES2765891T3 (en)
HK (1) HK1198386A1 (en)
HU (1) HUE036010T2 (en)
IL (1) IL233154A (en)
IN (1) IN2014CN04676A (en)
MX (1) MX351471B (en)
NO (1) NO2794597T3 (en)
NZ (1) NZ626176A (en)
PH (1) PH12014501365B1 (en)
PL (1) PL2794597T3 (en)
PT (1) PT2794597T (en)
RU (1) RU2630677C2 (en)
SG (1) SG11201403402VA (en)
TW (1) TWI613199B (en)
WO (1) WO2013093484A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI577665B (en) 2010-02-11 2017-04-11 必治妥美雅史谷比公司 Macrocycles as factor xia inhibitors
ES2562903T3 (en) * 2011-07-13 2016-03-09 Santen Pharmaceutical Co., Ltd New compound that has PARP inhibitory activity
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CA2851810C (en) 2011-10-14 2020-01-07 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103987696B (en) 2011-10-14 2016-12-21 百时美施贵宝公司 Substituted tetrahydro isoquinoline compound as factor XI, plasma thromboplastin antecedent A inhibitor
BR112014015669A8 (en) * 2011-12-21 2017-07-04 Ono Pharmaceutical Co new pyridinone and primidinone derivatives as xla factor inhibitors
UY34539A (en) * 2011-12-23 2013-06-28 Millennium Pharm Inc HETEROARILOS AND USES OF THE SAME
WO2014014050A1 (en) 2012-07-19 2014-01-23 大日本住友製薬株式会社 1-(cycloalkyl-carbonyl)proline derivative
DK2882734T3 (en) 2012-08-03 2017-01-30 Bristol-Myers Squibb Company Dihydropyridon as factor-xia inhibitors
WO2014022767A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9920034B2 (en) 2012-10-12 2018-03-20 Bristol-Myers Squibb Company Crystalline forms of a factor XIa inhibitor
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (en) 2013-03-25 2019-05-14 Squibb Bristol Myers Co Tetrahydroisoquinolines containing substituted azoles as inhibitors of factor XIa
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (en) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
CN105555767B (en) * 2013-07-23 2018-03-23 拜耳制药股份公司 Substituted oxo pyridine derivative and its purposes as factor XI, plasma thromboplastin antecedent A/ blood plasma
WO2015063093A1 (en) * 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
NO2760821T3 (en) 2014-01-31 2018-03-10
JP6505727B2 (en) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Macrocycles as factor XIA inhibitors with heterocyclic P2 'groups
WO2015123093A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3138839B1 (en) 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
WO2015164308A1 (en) 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN105658641B (en) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 Benzazole amide derivatives, its preparation method and its application in medicine
EP3180317A4 (en) 2014-07-28 2018-03-28 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
ES2714283T3 (en) 2014-09-04 2019-05-28 Squibb Bristol Myers Co Macrocycles of diamide that are inhibitors of FXIa
CN104311537B (en) * 2014-09-19 2016-08-24 广东东阳光药业有限公司 Containing pyrimidone acetyl substituents pyrazole compound and combinations thereof thing and purposes
US10077265B2 (en) 2014-09-24 2018-09-18 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (en) * 2014-10-01 2018-10-20
EP3231803B1 (en) * 2014-12-10 2020-07-01 ONO Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
RU2649141C2 (en) * 2015-04-20 2018-03-30 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 3,4-dimethyl-6-(3-pyridyl)-n-phenyl-2-oxo-1,2,3,6-tetrahydropyrimidine-5-carboxamide with antifungal activity against the candida albicans strain
EA036208B1 (en) 2015-07-09 2020-10-14 Байер Фарма Акциенгезельшафт Substituted oxopyridine derivatives
RU2653511C2 (en) * 2015-07-29 2018-05-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 4-methyl-n-2,4-dimethylphenyl-6-(3-fluorophenyl)-2-thyoxo-1,2,3,6-tetragydropyrimidine-5-carboxamide that has analgetic action
KR20180031037A (en) 2015-08-05 2018-03-27 브리스톨-마이어스 스큅 컴퍼니 Newly substituted glycine-induced FXIA inhibitors
CN106496249B (en) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 Oxazoloindole derivative, preparation method and medical application thereof
EP3371162A4 (en) * 2015-10-29 2019-04-24 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
TW201808908A (en) 2016-08-22 2018-03-16 美商默沙東藥廠 Factor XIa inhibitors
TW201811748A (en) * 2016-08-31 2018-04-01 江蘇恆瑞醫藥股份有限公司 Oxo-pyridine amide derivatives, preparation process thereof and pharmaceutical use thereof
JP6664552B2 (en) 2016-10-07 2020-03-13 ミツビシ ハイテク ペイパー ユーロップ ゲー・エム・ベー・ハーMitsubishi HiTec Paper Europe GmbH Thermal recording material
EP3305538A1 (en) 2016-10-07 2018-04-11 Mitsubishi HiTec Paper Europe GmbH Heat sensitive recording material
CN106950319B (en) * 2017-04-20 2019-08-30 西安科技大学 A method of detection spy's Lu Quban optical isomer content
KR20200127196A (en) * 2018-02-27 2020-11-10 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Crystalline form of oxophicolinamide derivative and method for preparing same
WO2020094156A1 (en) * 2018-11-11 2020-05-14 上海海雁医药科技有限公司 Diheterocycle-substituted pyridine-2(1h)-ketone derivative, preparation method therefore and pharmaceutical use thereof
WO2020111268A1 (en) * 2018-11-30 2020-06-04 小野薬品工業株式会社 Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one
CN109836360A (en) * 2019-03-19 2019-06-04 南京恩泰医药科技有限公司 A kind of preparation method and midbody compound of toluenesulfonic acid Yi Dushaban intermediate

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0042675A1 (en) 1980-06-20 1981-12-30 Norton Company Method of mounting a grinding wheel on a spindle
EP0110955B1 (en) 1982-05-18 1995-08-23 University Of Florida Brain-specific drug delivery
CA1241120A (en) 1985-10-01 1988-08-23 Sami A. Aly Alternate mark inversion (ami) receiver
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
DE4221583A1 (en) * 1991-11-12 1993-05-13 Bayer Ag SUBSTITUTED BIPHENYLPYRIDONE
DE4407488A1 (en) 1994-03-07 1995-09-14 Bayer Ag Use of bi:phenylyl-methyl- or phenyl-pyridyl-methyl- pyridone cpds.
SI1490064T1 (en) 2002-02-14 2010-01-29 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
KR20060041309A (en) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1828147A1 (en) 2004-10-15 2007-09-05 AstraZeneca AB Quinoxalines as b-raf inhibitors
ZA200704913B (en) 2004-11-24 2008-09-25 Vertex Pharma 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
EP1910342A1 (en) 2005-07-29 2008-04-16 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
ES2365815T3 (en) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Analogs of arilpropionamida, arilacrilamida, arilpropinamida or arilmetilurea as inhibitors of the xia factor.
NZ568595A (en) 2005-12-14 2010-04-30 Squibb Bristol Myers Co Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
WO2008062905A2 (en) * 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
US8410155B2 (en) 2006-12-15 2013-04-02 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors
MX2010006379A (en) 2007-12-11 2010-09-07 Schering Corp Gamma secretase modulators.
JP5537442B2 (en) * 2008-03-13 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Pyridazine derivatives as factor XIA inhibitors
CA2748862A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
AR083313A1 (en) 2010-10-07 2013-02-13 Takeda Pharmaceutical DERIVATIVES OF 1,4-OXAZEPAN USEFUL AS INHIBITORS OF THE RECOVERY OF SUPERIOR MONOAMINE
BR112014015669A8 (en) * 2011-12-21 2017-07-04 Ono Pharmaceutical Co new pyridinone and primidinone derivatives as xla factor inhibitors

Also Published As

Publication number Publication date
JP6137193B2 (en) 2017-05-31
KR20140103286A (en) 2014-08-26
HK1198386A1 (en) 2015-04-17
SG11201403402VA (en) 2015-01-29
WO2013093484A1 (en) 2013-06-27
JP2017160239A (en) 2017-09-14
EP3290413B1 (en) 2019-11-13
AU2012356374B2 (en) 2017-06-22
US10717738B2 (en) 2020-07-21
EP3290413A1 (en) 2018-03-07
PH12014501365A1 (en) 2014-09-22
AU2012356374A8 (en) 2014-08-07
CA2859604C (en) 2019-12-17
BR112014015669A8 (en) 2017-07-04
HUE036010T2 (en) 2018-06-28
US20170305917A1 (en) 2017-10-26
PT2794597T (en) 2018-01-16
ES2655669T3 (en) 2018-02-21
CA2859604A1 (en) 2013-06-27
EP2794597B1 (en) 2017-11-15
EP3290413B9 (en) 2020-04-29
US20150152112A1 (en) 2015-06-04
TWI613199B (en) 2018-02-01
MX2014007269A (en) 2014-07-22
MX351471B (en) 2017-10-17
EP2794597A1 (en) 2014-10-29
DK2794597T3 (en) 2018-01-15
KR102011534B1 (en) 2019-08-16
ES2765891T3 (en) 2020-06-11
CN104136431B (en) 2017-03-15
PL2794597T3 (en) 2018-03-30
AU2012356374A1 (en) 2014-07-10
IL233154A (en) 2016-12-29
US9732085B2 (en) 2017-08-15
PH12014501365B1 (en) 2014-09-22
RU2630677C2 (en) 2017-09-12
CN104136431A (en) 2014-11-05
NO2794597T3 (en) 2018-04-14
RU2014129797A (en) 2016-02-10
JP6447660B2 (en) 2019-01-09
BR112014015669A2 (en) 2017-06-13
JP2015500868A (en) 2015-01-08
TW201339157A (en) 2013-10-01
IN2014CN04676A (en) 2015-09-18
NZ626176A (en) 2015-09-25

Similar Documents

Publication Publication Date Title
HK1245780B (en) Imidazopyrrolidinone compounds
IL268013D0 (en) Tetrahydropyrazolopyrimidine compounds
IL265897D0 (en) Substituted imidazopyridinyl-aminopyridine compounds
IL237341D0 (en) Pro-neurogenic compounds
HRP20190994T1 (en) New compounds
HK1203196A1 (en) Substituted benzylpyrazoles
HK1195016A1 (en) Protein-polymer-drug conjugates --
DK3505720T3 (en) Cementering under styret tryk
ZA201401553B (en) Cyclopropaneamine compound
IL233154D0 (en) Compounds
IL230280A (en) Breastshield unit
EP2755962A4 (en) Azaindazoles
GB201214750D0 (en) Compounds
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2790561A4 (en) Dishmachine
GB201114103D0 (en) Novel compounds
GB201204966D0 (en) Djml
DK3424953T3 (en) Terapeutiske antistoffer
GB201118652D0 (en) New compounds
GB201106799D0 (en) Novel compounds
EP2715659A4 (en) Überfeed
GB201116641D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
GB201106395D0 (en) Compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed